13
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The effectiveness of long-term course of Sterimar Mn nasal spray for treatment of the recurrence rates of acute allergic rhinitis in patients with chronic allergic rhinitis

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The “cost of illness” of the acute allergic rhinitis (AR) episodes in patients with chronic AR is very high in terms of therapy and quality of life. AR represents a worldwide health problem; despite the fact that many standardized treatments have been proposed and used, the recurrence rate of acute rhinitis episodes in springtime is always higher.

          Materials and methods

          Sixty consecutive patients (13 F and 17 M in group A, 15 F and 15 M in group B; p=0.60) with chronic AR were enrolled in this prospective, controlled clinical trial. Thirty patients were treated daily for the same 5 months of the following year (2013) with isotonic seawater nasal spray enriched with manganese (Sterimar Mn; 4 puffs/day), whereas 30 patients received only the standard care and were used as control group.

          Results

          A 5 months course treatment with the nasal Sterimar Mn was able to decrease, significantly ( p<0.001), the number of episodes of acute AR (6.33 episodes in the group of treated patients versus 9.33 episodes in control group). Also, the 5 months quality of life reduced over time (Visual Analogue Scale 5th month 9.90 in treated group versus Visual Analogue Scale 5th month 8.72 in control group: p<0.001) without the typical adverse effects of the AR standard care therapy.

          Conclusion

          This study shows the effectiveness of the use of Sterimar Mn for a 5 months therapy in terms of reduction of the number of episodes of acute AR and effectiveness of intrasubject improvement of Visual Analog Scale (quality of life).

          Video abstract

          Related collections

          Most cited references 13

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical practice guideline: Allergic rhinitis.

          Allergic rhinitis (AR) is one of the most common diseases affecting adults. It is the most common chronic disease in children in the United States today and the fifth most common chronic disease in the United States overall. AR is estimated to affect nearly 1 in every 6 Americans and generates $2 to $5 billion in direct health expenditures annually. It can impair quality of life and, through loss of work and school attendance, is responsible for as much as $2 to $4 billion in lost productivity annually. Not surprisingly, myriad diagnostic tests and treatments are used in managing this disorder, yet there is considerable variation in their use. This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm-benefit balance of various diagnostic and management options.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis.

            Allergic rhinitis (AR) severity is evaluated using scores such as Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) and total symptom score (TSS). However, a simple assessment is needed to enable physicians to evaluate the severity of the AR and the efficacy of the treatment. The main objective was to validate visual analogue scale (VAS) as a simple quantitative tool to assess the burden of AR in primary care. The study was multi-centre prospective observational conducted in patients consulting general practitioners for symptomatic rhinitis. VAS, RQLQ and TSS6 were assessed at the consultation day and 14 days later, and changes were analysed using paired test. Correlations between VAS, RQLQ and TSS6 were assessed. Cut-off levels for VAS, which discriminate significant from insignificant changes, were established using Receiver Operating Characteristic curves. A total of 990 patients were included in the study. According to allergic rhinitis and its impact on asthma classification, mild intermittent rhinitis was diagnosed in 20% patients, mild persistent in 17%, moderate/severe intermittent in 15% and moderate/severe persistent in 48%, at the consultation day. At day-14, rhinitis symptoms and QoL improved significantly in almost all patients. Impairment incurred by AR and assessed with VAS improved also. The established cut-off variation of 23 mm for VAS was associated with a cut-off variation of 0.5 for RQLQ. Sensitivity analysis with RQLQ and TSS6 scales confirmed the aptitude of the cut-off value (23 mm) to discriminate changes in symptoms and QoL. The VAS can detect with high sensitivity the variations of symptoms and QoL in patients with AR. © 2013 Blackwell Publishing Ltd.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Saline irrigation for chronic rhinosinusitis.

              This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Nasal saline irrigation is commonly used to improve patient symptoms.
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                Drug Design, Development and Therapy
                Dove Medical Press
                1177-8881
                2018
                03 April 2018
                : 12
                : 705-709
                Affiliations
                [1 ]ENT Department, Head and Neck Surgery, University “Sapienza”, Rome, Italy
                [2 ]ENT Department, Head and Neck Surgery, Lamezia Terme Hospital, Calabria, Italy
                Author notes
                Correspondence: Michele Grasso, ENT Department, Head and Neck Surgery, University “Sapienza”, Rome, via San Silverio, 15, Rome 00165, Italy, Tel +39 333 461 6797, Email michelegrasso87@ 123456libero.it
                Article
                dddt-12-705
                10.2147/DDDT.S145173
                5892953
                29662303
                © 2018 Grasso et al. This work is published and licensed by Dove Medical Press Limited

                The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                Categories
                Original Research

                Comments

                Comment on this article